Joint Clinical Trials Office

You are here

A Double-Blind, Double-Dummy Phase II Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects with Essential Thrombocythemia Who Are Resistant to or Intolerant to Hydroxyurea

Clinical Trial Details

The primary purpose of the Study is to compare the safety, tolerability and effectivenss of ruxolitinib with that of anagrelide in patients with essential thrombocythemia (ET) who are resistant or intolerant to Hydroxyurea. 

Ruxolitinib is an investigational drug that is being studied in the treatment of ET. Ruxolitinib has been approved by the FDA under the trade name JAKAFI for the treatment of rare blood diorders called Myelofibrosis in 2011 and Polycythemia vera in 2014. It is a medication that blocks certain proteins called tyrosine kinases. It works by shutting down a pathway that is overactive in your disease. The medicine is take by mouth twice a day. 

Anagrelide is a platelet-reducing medication and has been approved by the FDA for the treatment of patients with abnormally elevated platelet counts. Platelets are important for blood clotting. 

Key Eligibility: 
  • Subjects must be 18 or older 
  • Subject must have a diagnosis of essential thrombocythemia 
  • Subjects must be intolerant or resistant to Hydroxyurea 
  • Subject must not have been previously treated with anagrelide or JAK inhibitors 
  • Detailed eligibility will be reviewed when you contact the study team 

Study contact by location

Upper East Side - Manhattan


Yulia Dault, RN
(212) 746-4829

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:






Open to Enrollment

Age Group